Sexual Wellness · PT-141
PT-141 for men.A central-nervous-system pathway, used off label.
PT-141 (bremelanotide) is a melanocortin-receptor agonist that acts in the central nervous system. It works through a different mechanism than PDE5 inhibitors like sildenafil and tadalafil. In men, it is used off label for sexual desire and arousal.
FDA status
Bremelanotide is FDA-approved as Vyleesi for premenopausal HSDD in women. Use in men is off label, prescribed at provider discretion based on clinical picture, with informed consent. Compounded preparations are dispensed by 503A pharmacies under valid prescription.
A note on care
Discreet, dignified, evidence-graded.
PT-141 sits in a different category from sildenafil and tadalafil. Those are vascular drugs, blocking the breakdown of cGMP so blood flow holds during arousal. PT-141 is upstream of vascular events. It signals to melanocortin-4 receptors in the hypothalamus and is associated with desire and arousal effects, not erection mechanics directly.
We discuss whether PT-141 is appropriate for your situation after reviewing your hormone panel, cardiovascular history, and current medications. PT-141 is not a substitute for treating low testosterone, vascular ED, or unmanaged metabolic disease.
How it works
Melanocortin signaling, not vascular blockade.
PT-141 binds preferentially to melanocortin-4 receptors (MC4R) in central nervous system pathways linked to sexual response. Unlike PDE5 inhibitors, it does not directly affect vascular smooth muscle. The clinical effect tends to involve desire and arousal alongside any erection effect, which is why patients who have responded poorly to PDE5 inhibitors sometimes find PT-141 useful, and vice versa.
Onset is typically 30 to 60 minutes from injection. Window of effect is several hours. Dosing is per-event subcutaneous, not daily.
In context
Where this fits among other options.
PDE5 inhibitors (sildenafil, tadalafil)
First-line for vascular ED. Direct mechanism. Generally well tolerated. PT-141 is not a replacement when vascular ED is the driver.
TRT or enclomiphene
Address low testosterone where clinically indicated. PT-141 does not correct hypogonadism. We treat low testosterone first before considering PT-141 as a stand-alone.
Candidacy
Who this is appropriate for.
- Men with desire or arousal issues despite normal vascular function
- Men with partial response to PDE5 inhibitors
- Patients seeking a per-event option without daily dosing
Safety considerations
What we screen for.
- Cardiovascular history (uncontrolled hypertension is a contraindication)
- Current medications including antihypertensives
- Active or recent malignancy
- Concurrent peptide stack and dose-stacking risk
Frequently asked
Frequently asked questions.
Subcutaneous injection, typically per event 30 to 60 minutes before sexual activity. Not daily. Your provider reviews technique at your in-clinic visit.
No. PT-141 acts on the CNS arousal pathway, not the vascular pathway. For vascular ED, PDE5 inhibitors remain first line. PT-141 is a different tool, sometimes useful when desire is the limiting factor or PDE5 response is partial.
Common: transient flushing, mild nausea (especially first dose), and a transient blood-pressure increase. Less common: headache, injection-site reaction. Uncontrolled hypertension is a contraindication. Your provider screens these at the Good Faith Exam.
Disclose any competitive athletic status to your provider before initiating any peptide. Several peptides offered through the Genesis Longevity program appear on the WADA prohibited list.
Next step
Schedule a private consultation.
Your conversation is confidential. Provider-led, evidence-graded, no pressure.